» Articles » PMID: 38472612

Optimization of MHealth Behavioral Interventions for Patients with Chronic Lymphocytic Leukemia: the HEALTH4CLL Study

Overview
Journal J Cancer Surviv
Specialty Oncology
Date 2024 Mar 13
PMID 38472612
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: This pilot study of a diet and physical activity intervention (HEALTH4CLL) was conducted to reduce fatigue and improve physical function (PF) in patients with chronic lymphocytic leukemia (CLL).

Methods: The HEALTH4CLL study used a randomized factorial design based on the multiphase optimization strategy (MOST). Patients received diet, exercise, and body weight management instructional materials plus a Fitbit and were randomized to undergo one of 16 combinations of 4 evidence-based mHealth intervention strategies over 16 weeks. Patients' fatigue, PF, health-related quality of life, behavior changes, and program satisfaction and retention were assessed. Paired t-tests were used to examine changes in outcomes from baseline to follow-up among patients. Factorial analysis of variance examined effective intervention components and their combinations regarding improvement in fatigue and PF scores.

Results: Among 31 patients, we observed significant improvements in fatigue (+ 11.8; t = 4.08, p = 0.001) and PF (+ 2.6; t = 2.75, p = 0.01) scores. The combination of resistance and aerobic exercise with daily self-monitoring was associated with improved fatigue scores (β = 3.857, SE = 1.617, p = 0.027). Analysis of the individual components of the MOST design demonstrated greater improvement in the PF score with resistance plus aerobic exercise than with aerobic exercise alone (β = 2.257, SE = 1.071, p = 0.048).

Conclusions: Combined aerobic and resistance exercise and daily self-monitoring improved PF and reduced fatigue in patients with CLL.

Implications For Cancer Survivors: This pilot study supported the feasibility of a low-touch mHealth intervention for survivors of CLL and provided preliminary evidence that exercising, particularly resistance exercise, can improve their symptoms and quality of life.

Citing Articles

A 16-week progressive exercise training intervention in treatment-naïve chronic lymphocytic leukaemia: a randomised-controlled pilot study.

Brown F, Oliver R, Eddy R, Causer A, Emery A, Collier-Bain H Front Oncol. 2024; 14:1472551.

PMID: 39703835 PMC: 11655450. DOI: 10.3389/fonc.2024.1472551.

References
1.
Burger J . Treatment of Chronic Lymphocytic Leukemia. N Engl J Med. 2020; 383(5):460-473. DOI: 10.1056/NEJMra1908213. View

2.
Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner C . Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014; 370(12):1101-10. DOI: 10.1056/NEJMoa1313984. View

3.
Shanafelt T, Wang X, Kay N, Hanson C, OBrien S, Barrientos J . Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. N Engl J Med. 2019; 381(5):432-443. PMC: 6908306. DOI: 10.1056/NEJMoa1817073. View

4.
Thompson P, Tam C, OBrien S, Wierda W, Stingo F, Plunkett W . Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2015; 127(3):303-9. PMC: 4760129. DOI: 10.1182/blood-2015-09-667675. View

5.
Hallek M, Cheson B, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H . iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018; 131(25):2745-2760. DOI: 10.1182/blood-2017-09-806398. View